REVIEW ARTICLE



The effect of holmium laser resection versus standard transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis

Changlong Li¹ · Liang Gao¹ · Jindong Zhang¹ · Xiaokang Yang¹ · Chuan Liu¹

Received: 19 November 2019 / Accepted: 22 January 2020 / Published online: 31 January 2020 © Springer-Verlag London Ltd., part of Springer Nature 2020

Abstract

To explore the advantages and limitations of holmium laser resection of the bladder tumor (HOLRBT) versus standard transurethral resection of the bladder tumor (TURBT) in the treatment of non-muscle-invasive bladder cancer (NMIBC), the eligible studies were selected from the following databases: PubMed, Cochrane Library, and Embase. Studies comparing HOLRBT and TURBT for patients with NMIBC were included. The outcomes of interest were time of operation, catheterization and hospitalization, rates of recurrence, and perioperative complications, including obturator nerve reflex, bladder perforation, bladder irritation, and urethral stricture. Results of all data were compared and analyzed by Review Manager 5.3. A total of 9 comparative studies were finally included for this analysis. Pooled data demonstrated that HOLRBT significantly reduced the time to catheterization and hospitalization, the rate of recurrence in 2 years of follow-up, obturator nerve reflex, bladder perforation, and bladder irritation, compared with those in TURBT, respectively. However, no significant difference found between HOLRBT and TURBT in the time of operation, rate of recurrence in 1-year follow-up, and urethral stricture. The results of this research reached that HOLRBT would be a better choice than TURBT for patients with NMIBC.

Keywords Non-muscle-invasive bladder cancer · Holmium laser · Transurethral resection · Meta-analysis

Background

Bladder cancer is the tenth most common cancer worldwide, with estimated 549,000 new cases and 200,000 deaths in 2018 [1]. According to the depth of invasion, bladder cancer was divided into two types, non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive disease, and 75% of bladder cancer belongs to the former [2]. NMIBC is defined as the tumor is confined to the mucosa or submucosa of bladder.

Previously, the patients with NMIBC were usually treated by transurethral resection of the bladder tumor (TURBT) combined with intravesical chemotherapy or immunotherapy [3]. This strategy above was the "golden standard" according to the guideline

Changlong Li and Liang Gao contributed equally and should share the first author

Chuan Liu liuchuan100@hospital.cqmu.edu.cn of European Association of Urology [4]. However, the limitations of TURBT were gradually presented, such as the occurrences of obturator nerve reflex, bladder perforation, bladder irritation, and postoperative bleeding. Holmium laser resection of the bladder tumor (HOLRBT) was applied to overcome these shortages, which showed satisfactory outcomes, especially in tissue cutting, vaporization, and hemostasis [5]. The aim of our study was to compare the safety and effectiveness of HOLRBT and TURBT for patients with NMIBC.

Methods

Search strategy

This study was performed following the principle of preferred reporting items for systematic review and meta-analysis protocols (PRISMA) [6]. The databases included PubMed, Cochrane Library, and EMBASE and were respectively searched with the term in title/abstract: "superficial bladder cancer," "non-muscle-invasive bladder cancer," "holmium

¹ Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China

laser," and "transurethral resection" up to March 2019. The reference lists from the identified documents were also searched. To avoid data duplication, the latest report was used if multiple studies described the same population.

Inclusion and exclusion criteria

All comparative studies, including randomized controlled studies (RCT), cohort studies (CS), and case-control studies (CCS), focusing on HOLRBT and TURBT for patients with NMIBC were included. On the other hand, studies would be excluded if (1) studies included patients with muscle-invasivebladder cancer or distant metastasis; (2) none of the following outcomes of interest were reported, including time of operation, catheterization and hospitalization, rate of recurrence, and complications, such as obturator nerve reflex, bladder perforation, bladder irritation, and urethral stricture; (3) data of studies were not sufficient for a meta-analysis; and (4) studies presented as conference abstracts.

Data extraction

Data were extracted from these studies by 2 independent reviewers. If the two reviewers disagreed, a consensus was reached after a discussion between them. To keep the baselines as similar as possible, the only comparison between HOLRBT and TURBT was extracted when the patients were divided into \geq 3 groups in studies. When articles were not written in English, they were translated for data extraction if possible.

Outcomes of interest

The outcomes of interest were time of operation, catheterization and hospitalization, rate of recurrence, and perioperative complications, including obturator nerve reflex, bladder perforation, bladder irritation, and urethral stricture.

Quality assessment and statistical analysis

The level of evidence of the included studies was graded according to the criteria by the Centre for Evidence-Based Medicine in Oxford, UK [7]. In addition, the quality of each included CS or CCS was evaluated by the Newcastle-Ottawa scale (NOS). The NOS was a widely used quality assessment method in meta-analysis [8]. In the modified Newcastle-Ottawa scale, a score of 1–9 stars was allocated, and more stars stood for higher quality.

The meta-analysis was performed by Review Manager 5.3. The odd ratio (OR) and mean difference (MD) were used for describing results of dichotomous and continuous variables, respectively. All results were reported with 95% confidence intervals (CI). The P < 0.05 was regarded to be statistically significant.

In addition, statistical heterogeneities among trials were evaluated by I^2 and χ^2 tests. I^2 value of 25%, 50%, and 75% was corresponded to low, medium, and high levels of heterogeneity, respectively. When $I^2 < 50\%$ and P > 0.10, a fixed-effect model was used. Otherwise, the random-effect model was applied.

Results

Study selection

Through the search strategy, a total of 317 articles were initially found. After software and manual checking, 85 papers were excluded because of duplications. Then, 203 documents were excluded after screening of the title and abstract. Of the 29 remaining records, 20 articles were excluded after evaluation of the full text. Finally, 9 studies [9-17] with a total of 1166 patients were included in the meta-analysis, in which



Fig. 1 Flow diagram of study

Characteristics of included studies

Table 1

	IIIIEIVAI									<i>(u)</i>				
								Latera	1 Other	Ta T1	PUNLM	IP Low	High	
2b	2012-2015	HOLRBT India	23	66.3 ± 9.8	15	8	15.8 ± 3.1	10	13	15 8	4	16		-
		TURBT	27	67.1 ± 8.3	18	6	14.1 ± 2.3	11	16	16 11	5	20	5	
2b	2006-2007	HOLRBT China	64	61	48	16	NA	30	34	42 22	36	19	6	7
		TURBT	90	65	68	22	NA	36	54	60 30	57	25	8	
2b	2009-2013	HOLRBT China	70	59.97 ± 5.75	45	25	15.8 ± 5.1	28	42	37 33	15	48	2	NA
		TURBT	70	57.87 ± 4.99	48	22	15.3 ± 2.0	25	45	35 35	18	46	9	
3b	2010-2014	HOLRBT Europe	50	62.2 ± 12.3	36	14	26.3 ± 7.9	NA	NA	29 21	0	23	27	8
		TURBT	156	67.5 ± 10.7	125	31	21.8 ± 9.07	NA	NA	83 62	0	72	84	
; 3b	2003-2005	HOLRBT China	26	65	21	5	24 ± 6.25	NA	NA	NA NA	NA	NA	NA	9
		TURBT	38	57	28	10	27 ± 9.25	NA	NA	NA NA	NA	NA	NA	
; 3b	NA	HOLRBT Italy	50	64.5	39	11	NA	NA	NA	43 7	NA	NA	NA	7
		TURBT	50	65.7	40	10	NA	NA	NA	46 4	NA	NA	NA	
2b	2005-2009	HOLRBT China	64	72.5	52	12	18.5 ± 7.75	25	39	36 28	5	39	20	7
		TURBT	109	73.7	87	22	16.2 ± 6.17	46	63	65 44	6	99	34	
3b	2006-2007	HOLRBT China	25	65.76 ± 12.4	NA	NA	13.8 ± 5.8	NA	NA	19 6	3	18	4	8
		TURBT	42	66.26 ± 11.0	NA	NA	15.4 ± 6.6	NA	NA	30 12	7	26	6	
; 3b	2003-2005	HOLRBT China	101	NA	79	22	NA	NA	NA	67 34	NA	NA	NA	7
		TURBT	111	NA	92	19	NA	NA	NA	70 41	NA	NA	NA	
		HOLRBT	473	64.34	335	113	19.14	93	128	288 159	63	163	70	
		TURBT	693	66.17	506	145	18.76	118	178	405 239	96	255	143	
ction of	bladder tumo	rr; TURBT transurethr	al resection of b	ladder tumor; L	<i>OE</i> leve	l of eviden	ce; NOS Newcastle	e-Ottawa	scale; <i>NA</i>	not availa	ble			
	2b 2b 3b 3b 3b 3b tion of	 2b 2012–2015 2b 2006–2007 2b 2009–2013 3b 2010–2014 3b 2010–2014 3b 2003–2005 3b 2005–2009 3b 2005–2007 3b 2003–2005 dition of bladder tunno 	2b 2012-2015 HOLRBT India 2b 2006-2007 HOLRBT China 2b 2009-2013 HOLRBT China 2b 2009-2013 HOLRBT China 3b 2010-2014 HOLRBT China 3b 2010-2014 HOLRBT Europe 3b 2010-2014 HOLRBT Europe 3b 2003-2005 HOLRBT China 3b 2005-2009 HOLRBT Italy 3b 2005-2009 HOLRBT China 3b 2005-2009 HOLRBT China 3b 2005-2009 HOLRBT China 3b 2005-2009 HOLRBT China 3b 2005-2005 HOLRBT China 3b <td< td=""><td>2b 2012-2015 HOLRBT India 23 7b 2006-2007 HOLRBT China 64 7b 2006-2013 HOLRBT 70 7b 2009-2013 HOLRBT 70 7b 2009-2014 HOLRBT 70 7b 2010-2014 HOLRBT 70 7b 2010-2014 HOLRBT 70 7b 2010-2014 HOLRBT 70 7b 2003-2005 HOLRBT 70 7b 2003-2005 HOLRBT 70 7b 2003-2009 HOLRBT 70 7b 2005-2009 HOLRBT 50 7b 2005-2009 HOLRBT 64 7b 2005-2009 HOLRBT 70 7b 2005-2009 HOLRBT 7109 7b 2005-2005 HOLRBT 710 7b 2005-2005 HOLRBT 71 7b 2005-2005 HOLRBT 42 7b 2005-2005 HOLRBT 42 7b 2005-2005</td><td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 7URBT 27 67.1 ± 8.3 70 5006-2007 HOLRBT 64 61 70 5009-2013 HOLRBT 90 65 70 2009-2013 HOLRBT 70 59.97 ± 5.75 71 70 59.97 ± 5.75 787 ± 4.99 70 70 59.97 ± 5.75 787 ± 4.99 71 70 70 59.97 ± 5.75 70 70 59.97 ± 5.75 787 ± 4.99 71 70 70 59.97 ± 5.75 70 2010-2014 HOLRBT 70 57.87 ± 4.99 71 70 70 57.87 ± 4.99 57 71 70 70 50 65.75 ± 11.07 71 70 70 50 65.75 71 70 70 50 65.76 73 70 70 70 73.7 74 109 73.7 70 73.7 75 70 206 65.76 ± 11</td><td>2b $2012-2015$ HOLRBT India 23 66.3 ± 9.8 15 2b $7006-2007$ HOLRBT 27 67.1 ± 8.3 18 2b $2006-2007$ HOLRBT 70 59.97 ± 5.75 45 2b $2009-2013$ HOLRBT 70 59.97 ± 5.75 45 3b $2010-2014$ HOLRBT 70 59.97 ± 5.75 45 3b $2003-2005$ HOLRBT 156 67.5 ± 10.7 125 3b $2003-2006$ HOLRBT $181y$ 50 65.7 ± 12.4 80 3b $2005-2009$ HOLRBT $181y$ 50 65.7 ± 12.4 87 3b $2005-2000$ HOLRBT 109</td><td>2b $2012-2015$ HOLRBT India 23 66.3 ± 9.8 15 8 2b $TURBT$ 27 67.1 ± 8.3 18 9 2b $2006-2007$ HOLRBT China 64 61 48 16 2b $2006-2007$ HOLRBT China 64 61 48 16 2b $2009-2013$ HOLRBT China 70 59.97 ± 5.75 45 25 3b $2009-2014$ HOLRBT Europe 50 65.22 ± 12.3 36 14 3b $2010-2014$ HOLRBT Europe 50 62.2 ± 12.3 36 14 3b $2003-2005$ HOLRBT 156 67.5 ± 10.7 125 31 3b NA HOLRBT 1181 50 65.76 ± 12.4 90 10 3b $2005-2009$ HOLRBT Inal 72.5 52 12 3b $2005-2009$ HOLRBT 109 73.7 87 20 12</td><td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 2b 2006-2007 HOLRBT China 64 61 48 16 NA 2b 2006-2007 HOLRBT China 64 61 48 16 NA 2b 2006-2003 HOLRBT 90 65 68 22 NA 2b 2009-2013 HOLRBT 70 59.97 ± 5.75 45 25 15.8 ± 5.1 3b 2010-2014 HOLRBT 70 59.97 ± 5.75 48 20 15.3 ± 2.0 3b 2010-2014 HOLRBT 156 67.5 ± 10.7 125 31 21.8 ± 9.07 3b 2010-2005 HOLRBT 156 67.5 ± 10.7 125 31 21.8 ± 9.07 3b 2003-2005 HOLRBT 181y 50 65.7 ± 10.7 125 11 NA 3b NA HOLRBT 181y 50 52</td><td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 2b 2006-2007 HOLRBT 64 61 48 16 NA 30 2b 2006-2013 HOLRBT 90 65 68 22 NA 36 2b 2009-2013 HOLRBT 70 59.97 ± 5.75 45 25 15.8 ± 5.1 28 3b 2010-2014 HOLRBT 70 59.97 ± 5.75 45 25 15.8 ± 5.1 28 3b 2010-2014 HOLRBT 156 67.5 ± 10.7 125 31 21.8 ± 9.07 NA 3b 2003-2005 HOLRBT 156 67.5 ± 11.23 36 14 26.3 ± 7.9 NA 3b NA HOLRBT 156 67.5 ± 11.23 36 14 26.3 ± 7.9 NA 3b 2003-2005 HOLRBT 180 57 27 27 27 ± 9.25<!--</td--><td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 13 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 16 2b 2006-2007 HOLRBT 70 597 ± 5.75 48 16 NA 30 34 2b 2009-2013 HOLRBT 90 65 53 45 25 18 30 34 36 54 3b 2010-2014 HOLRBT 100 57.87 ± 4.99 48 22 15.8 ± 5.1 28 45 3b 2010-2014 HOLRBT 156 6.7.5 \pm 10.7 125 31 21.8 ± 9.07 NA NA 3b 2003-2005 HOLRBT 118 38 57 23 12.8 ± 9.07 NA NA 3b 2003-2005 HOLRBT 1181 50 65.5 ± 12.5 18.4 18 18.5 ± 5.7 18 18</td><td>2b 2012–2015 HOLRBT India 23 663±9.8 15 8 15.8±3.1 10 13 15 8 2b 2006–2007 HOLRBT China 27 67.1±8.3 18 9 14.1±2.3 11 16 16 11 2b 2006–2007 HOLRBT China 64 61 48 16 NA 36 54 42 22 2b 2009–2013 HOLRBT China 70 5997±5.75 45 25 15.8±5.1 28 42 37 33 33 33 36 14 26.3±7.9 NA <td< td=""><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>2b 2012-2015 HOLRBT India 23 66.3±9.8 15 8 15.8±3.1 10 13 15 8 4 16 2b 2006-2007 HOLRBT China 64 61 48 16 NA 30 34 42 23 57 29 2b 2006-2007 HOLRBT China 64 61 48 16 NA 36 54 60 30 57 28 29 33 15 48 23 18 46 30 57 23 55 15 35 18 46 30 57 28 19 16 16 16 16 17 55 20 23 18 46 30 57 23 18 46 30 30 31 15 87 36 14 20 23 18 46 30 30 31 36 36 36 36 36 36 36<td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 15 8 4 16 3 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 16 16 15 20 2</td></td></td<></td></td></td<>	2b 2012-2015 HOLRBT India 23 7b 2006-2007 HOLRBT China 64 7b 2006-2013 HOLRBT 70 7b 2009-2013 HOLRBT 70 7b 2009-2014 HOLRBT 70 7b 2010-2014 HOLRBT 70 7b 2010-2014 HOLRBT 70 7b 2010-2014 HOLRBT 70 7b 2003-2005 HOLRBT 70 7b 2003-2005 HOLRBT 70 7b 2003-2009 HOLRBT 70 7b 2005-2009 HOLRBT 50 7b 2005-2009 HOLRBT 64 7b 2005-2009 HOLRBT 70 7b 2005-2009 HOLRBT 7109 7b 2005-2005 HOLRBT 710 7b 2005-2005 HOLRBT 71 7b 2005-2005 HOLRBT 42 7b 2005-2005 HOLRBT 42 7b 2005-2005	2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 7URBT 27 67.1 ± 8.3 70 5006-2007 HOLRBT 64 61 70 5009-2013 HOLRBT 90 65 70 2009-2013 HOLRBT 70 59.97 ± 5.75 71 70 59.97 ± 5.75 787 ± 4.99 70 70 59.97 ± 5.75 787 ± 4.99 71 70 70 59.97 ± 5.75 70 70 59.97 ± 5.75 787 ± 4.99 71 70 70 59.97 ± 5.75 70 2010-2014 HOLRBT 70 57.87 ± 4.99 71 70 70 57.87 ± 4.99 57 71 70 70 50 65.75 ± 11.07 71 70 70 50 65.75 71 70 70 50 65.76 73 70 70 70 73.7 74 109 73.7 70 73.7 75 70 206 65.76 ± 11	2b $2012-2015$ HOLRBT India 23 66.3 ± 9.8 15 2b $7006-2007$ HOLRBT 27 67.1 ± 8.3 18 2b $2006-2007$ HOLRBT 70 59.97 ± 5.75 45 2b $2009-2013$ HOLRBT 70 59.97 ± 5.75 45 3b $2010-2014$ HOLRBT 70 59.97 ± 5.75 45 3b $2003-2005$ HOLRBT 156 67.5 ± 10.7 125 3b $2003-2006$ HOLRBT $181y$ 50 65.7 ± 12.4 80 3b $2005-2009$ HOLRBT $181y$ 50 65.7 ± 12.4 87 3b $2005-2000$ HOLRBT 109	2b $2012-2015$ HOLRBT India 23 66.3 ± 9.8 15 8 2b $TURBT$ 27 67.1 ± 8.3 18 9 2b $2006-2007$ HOLRBT China 64 61 48 16 2b $2006-2007$ HOLRBT China 64 61 48 16 2b $2009-2013$ HOLRBT China 70 59.97 ± 5.75 45 25 3b $2009-2014$ HOLRBT Europe 50 65.22 ± 12.3 36 14 3b $2010-2014$ HOLRBT Europe 50 62.2 ± 12.3 36 14 3b $2003-2005$ HOLRBT 156 67.5 ± 10.7 125 31 3b NA HOLRBT 1181 50 65.76 ± 12.4 90 10 3b $2005-2009$ HOLRBT Inal 72.5 52 12 3b $2005-2009$ HOLRBT 109 73.7 87 20 12	2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 2b 2006-2007 HOLRBT China 64 61 48 16 NA 2b 2006-2007 HOLRBT China 64 61 48 16 NA 2b 2006-2003 HOLRBT 90 65 68 22 NA 2b 2009-2013 HOLRBT 70 59.97 ± 5.75 45 25 15.8 ± 5.1 3b 2010-2014 HOLRBT 70 59.97 ± 5.75 48 20 15.3 ± 2.0 3b 2010-2014 HOLRBT 156 67.5 ± 10.7 125 31 21.8 ± 9.07 3b 2010-2005 HOLRBT 156 67.5 ± 10.7 125 31 21.8 ± 9.07 3b 2003-2005 HOLRBT 181y 50 65.7 ± 10.7 125 11 NA 3b NA HOLRBT 181y 50 52	2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 2b 2006-2007 HOLRBT 64 61 48 16 NA 30 2b 2006-2013 HOLRBT 90 65 68 22 NA 36 2b 2009-2013 HOLRBT 70 59.97 ± 5.75 45 25 15.8 ± 5.1 28 3b 2010-2014 HOLRBT 70 59.97 ± 5.75 45 25 15.8 ± 5.1 28 3b 2010-2014 HOLRBT 156 67.5 ± 10.7 125 31 21.8 ± 9.07 NA 3b 2003-2005 HOLRBT 156 67.5 ± 11.23 36 14 26.3 ± 7.9 NA 3b NA HOLRBT 156 67.5 ± 11.23 36 14 26.3 ± 7.9 NA 3b 2003-2005 HOLRBT 180 57 27 27 27 ± 9.25 </td <td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 13 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 16 2b 2006-2007 HOLRBT 70 597 ± 5.75 48 16 NA 30 34 2b 2009-2013 HOLRBT 90 65 53 45 25 18 30 34 36 54 3b 2010-2014 HOLRBT 100 57.87 ± 4.99 48 22 15.8 ± 5.1 28 45 3b 2010-2014 HOLRBT 156 6.7.5 \pm 10.7 125 31 21.8 ± 9.07 NA NA 3b 2003-2005 HOLRBT 118 38 57 23 12.8 ± 9.07 NA NA 3b 2003-2005 HOLRBT 1181 50 65.5 ± 12.5 18.4 18 18.5 ± 5.7 18 18</td> <td>2b 2012–2015 HOLRBT India 23 663±9.8 15 8 15.8±3.1 10 13 15 8 2b 2006–2007 HOLRBT China 27 67.1±8.3 18 9 14.1±2.3 11 16 16 11 2b 2006–2007 HOLRBT China 64 61 48 16 NA 36 54 42 22 2b 2009–2013 HOLRBT China 70 5997±5.75 45 25 15.8±5.1 28 42 37 33 33 33 36 14 26.3±7.9 NA <td< td=""><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>2b 2012-2015 HOLRBT India 23 66.3±9.8 15 8 15.8±3.1 10 13 15 8 4 16 2b 2006-2007 HOLRBT China 64 61 48 16 NA 30 34 42 23 57 29 2b 2006-2007 HOLRBT China 64 61 48 16 NA 36 54 60 30 57 28 29 33 15 48 23 18 46 30 57 23 55 15 35 18 46 30 57 28 19 16 16 16 16 17 55 20 23 18 46 30 57 23 18 46 30 30 31 15 87 36 14 20 23 18 46 30 30 31 36 36 36 36 36 36 36<td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 15 8 4 16 3 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 16 16 15 20 2</td></td></td<></td>	2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 13 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 16 2b 2006-2007 HOLRBT 70 597 ± 5.75 48 16 NA 30 34 2b 2009-2013 HOLRBT 90 65 53 45 25 18 30 34 36 54 3b 2010-2014 HOLRBT 100 57.87 ± 4.99 48 22 15.8 ± 5.1 28 45 3b 2010-2014 HOLRBT 156 6.7.5 \pm 10.7 125 31 21.8 ± 9.07 NA NA 3b 2003-2005 HOLRBT 118 38 57 23 12.8 ± 9.07 NA NA 3b 2003-2005 HOLRBT 1181 50 65.5 ± 12.5 18.4 18 18.5 ± 5.7 18 18	2b 2012–2015 HOLRBT India 23 663±9.8 15 8 15.8±3.1 10 13 15 8 2b 2006–2007 HOLRBT China 27 67.1±8.3 18 9 14.1±2.3 11 16 16 11 2b 2006–2007 HOLRBT China 64 61 48 16 NA 36 54 42 22 2b 2009–2013 HOLRBT China 70 5997±5.75 45 25 15.8±5.1 28 42 37 33 33 33 36 14 26.3±7.9 NA NA <td< td=""><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>2b 2012-2015 HOLRBT India 23 66.3±9.8 15 8 15.8±3.1 10 13 15 8 4 16 2b 2006-2007 HOLRBT China 64 61 48 16 NA 30 34 42 23 57 29 2b 2006-2007 HOLRBT China 64 61 48 16 NA 36 54 60 30 57 28 29 33 15 48 23 18 46 30 57 23 55 15 35 18 46 30 57 28 19 16 16 16 16 17 55 20 23 18 46 30 57 23 18 46 30 30 31 15 87 36 14 20 23 18 46 30 30 31 36 36 36 36 36 36 36<td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 15 8 4 16 3 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 16 16 15 20 2</td></td></td<>	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	2b 2012-2015 HOLRBT India 23 66.3±9.8 15 8 15.8±3.1 10 13 15 8 4 16 2b 2006-2007 HOLRBT China 64 61 48 16 NA 30 34 42 23 57 29 2b 2006-2007 HOLRBT China 64 61 48 16 NA 36 54 60 30 57 28 29 33 15 48 23 18 46 30 57 23 55 15 35 18 46 30 57 28 19 16 16 16 16 17 55 20 23 18 46 30 57 23 18 46 30 30 31 15 87 36 14 20 23 18 46 30 30 31 36 36 36 36 36 36 36 <td>2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 15 8 4 16 3 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 16 16 15 20 2</td>	2b 2012-2015 HOLRBT India 23 66.3 ± 9.8 15 8 15.8 ± 3.1 10 15 8 4 16 3 2b 2006-2007 HOLRBT 27 67.1 ± 8.3 18 9 14.1 ± 2.3 11 16 16 15 20 2

н	OLRBT		1	URBT			Mean Difference	Mean Difference
Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
58.2	15.8	23	55.6	13.5	27	5.6%	2.60 [-5.62, 10.82]	
29.2	14.1	64	39.6	10.1	90	11.6%	-10.40 [-14.44, -6.36]	
26.24	7.2	70	27.33	6.62	70	15.1%	-1.09 [-3.38, 1.20]	
29.65	12.46	50	27.19	11.96	156	11.8%	2.46 [-1.47, 6.39]	
26.24	7.2	70	27.33	6.62	70	15.1%	-1.09 [-3.38, 1.20]	
16.54	3.81	64	17.6	4.88	109	16.7%	-1.06 [-2.37, 0.25]	
26.24	7.2	25	27.33	6.62	42	12.7%	-1.09 [-4.55, 2.37]	
30.69	16.1	101	24.9	14.44	111	11.4%	5.79 [1.66, 9.92]	
		467			675	100.0%	-0.76 [-3.10, 1.58]	-
8.07; Cł	ni² = 34.	95, df =	= 7 (P <	0.0001)); l² = 8	0%		
Z = 0.63	(P = 0.	53)						Favours HOL RBT Favours TURBT
	H Mean 58.2 29.2 26.24 29.65 26.24 16.54 26.24 30.69 8.07; Cł Z = 0.63	HOLRBT Mean SD 58.2 15.8 29.2 14.1 26.24 7.2 29.65 12.46 26.24 7.2 16.54 3.81 26.24 7.2 30.69 16.1 8.07; $Chi^2 = 34.$ Z $Z = 0.63$ (P = 0.	HOLRBT Mean SD Total 58.2 15.8 23 29.2 14.1 64 26.24 7.2 70 29.65 12.46 50 26.24 7.2 70 16.54 3.81 64 26.24 7.2 25 30.69 16.1 101 467 8.07; Chi ² = 34.95, df = Z = 0.63 (P = 0.53)	HOLRB Total Mean Mean SD Total Mean 58.2 15.8 23 55.6 29.2 14.1 64 39.6 26.24 7.2 70 27.33 29.65 12.46 50 27.19 26.24 7.2 70 27.33 16.54 3.81 64 17.6 26.24 7.2 25 27.33 30.69 16.1 101 24.9 Horizon and the standard	HOLRBT Total Mean SD Mean SD Total Mean SD 58.2 15.8 23 55.6 13.5 29.2 14.1 64 39.6 10.1 26.24 7.2 70 27.33 6.62 29.65 12.46 50 27.19 11.96 26.24 7.2 70 27.33 6.62 16.54 3.81 64 17.6 4.88 26.24 7.2 25 27.33 6.62 30.69 16.1 101 24.9 14.44 Left 8.07; Chi ² = 34.95, df = 7 (P < 0.001)	HOLRBT Tutal Mean SD Tutal 58.2 15.8 23 55.6 13.5 27 29.2 14.1 64 39.6 10.1 90 26.24 7.2 70 27.33 6.62 70 29.65 12.46 500 27.19 11.96 156 26.24 7.2 70 27.33 6.62 70 29.65 12.46 500 27.19 11.96 156 26.24 7.2 70 27.33 6.62 70 16.54 3.81 644 17.6 4.88 109 26.24 7.2 25 27.33 6.62 42 30.69 16.1 101 24.9 14.44 111 total	HOLRBT TURBT Mean SD Total Mean SD Total Weight 58.2 15.8 23 55.6 13.5 27 5.6% 29.2 14.1 64 39.6 10.1 90 11.6% 26.24 7.2 70 27.33 6.62 70 15.1% 29.65 12.46 50 27.19 11.96 156 11.8% 26.24 7.2 70 27.33 6.62 70 15.1% 26.24 7.2 70 27.33 6.62 70 15.1% 16.54 3.81 64 17.6 4.88 109 16.7% 26.24 7.2 25 27.33 6.62 42 12.7% 30.69 16.1 101 24.9 14.44 111 14.4% 8.07; Chi ² = 34.95, df = 7 (P < 0.0001); l ² = 80'////////////////////////////////////	HOLRBT TURBT Mean Difference Mean SD Total Mean SD Total Weight IV. Random, 95% CI 58.2 15.8 23 55.6 13.5 27 5.6% 2.60 [-5.62, 10.82] 29.2 14.1 64 39.6 10.1 90 11.6% -10.40 [-14.44, -6.36] 26.24 7.2 70 27.33 6.62 70 15.1% -1.09 [-3.38, 1.20] 29.65 12.46 50 27.19 11.96 156 11.8% 2.46 [-1.47, 6.39] 26.24 7.2 70 27.33 6.62 70 15.1% -1.09 [-3.38, 1.20] 16.54 3.81 64 17.6 4.88 109 16.7% -1.06 [-2.37, 0.25] 26.24 7.2 25 27.33 6.62 42 12.7% -1.09 [-4.55, 2.37] 30.69 16.1 101 24.9 14.44 111 11.4% 5.79 [1.66, 9.92] 8.07; Chi ² = 34.95, df = 7 (P < 0.0001); l

Fig. 2 The results of operation time in meta-analysis

473 patients were treated by HOLRBT and 693 patients were treated by TURBT (Fig. 1).

Eight studies had described the gender of patients, in which 335 were males in HOLRBT group (74.8%) and 506 were males in the TURBT group (77.7%). The chi-square test showed that there was an insignificant difference in gender between two groups (P = 0.26). More, the pooled average age of patients between two groups was similar, which was calculated to be 64.34 in HOLRBT group and 66.17 in TURBT group, respectively. The characteristics of all available studies are shown in Table 1.

Totally, 1 RCT, 3 prospective CS, and 5 retrospective CCS were included in this analysis. According to the postoperative intravesical instilled chemotherapy scheme, 4 studies used mitomycin C, 2 studies used epirubicin, 2 studies used pirarubicin, and 1 study did not describe the chemotherapy scheme. Five studies [9–11, 15, 17] described a comparison of \geq 3 groups, in which only data describing HOLRBT and TURBT for NMIBC were extracted. One study was published in Chinese, however had an English abstract [12].

Outcomes of interest

Operation time

Eight studies including a total of 1142 patients [9–12, 14–17] had evaluated data of operation time, which revealed that there

was no significant difference in operation time between two groups (MD = -0.76, 95% CI [-3.10, 1.58], P = 0.53) (Fig. 2).

Catheterization time

When catheterization time was compared, 8 studies including 1142 patients [9–12, 14–17] were analyzed. Pooled data demonstrated a significantly less time in catheterization time in the HOLRBT group compared to TURBT group (MD = -1.02, 95% CI [-1.35, -0.68], P < 0.00001) (Fig. 3).

Hospitalization time

Seven studies including 1002 patients [9-11, 14-17] are pooled, which indicated that hospitalization time was significantly less in HOLRBT group compared to TURBT group (MD=-1.11, 95% CI [-1.65, -0.58], P < 0.0001) (Fig. 4).

1-year recurrence

Data describing the rate of 1-year recurrence were pooled from 5 studies [12–14, 16, 17] of 493 patients. Result of meta-analysis showed that there was an insignificant difference between two groups (OR = 0.72; 95% CI [0.45, 1.16], P = 0.18). Considering

	н	DLRB	г	т	URBT			Mean Difference		Mean	Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Ran	<u>dom, 9</u>	5% CI	
D'souza 2016	2.24	0.43	23	4.51	0.92	27	11.8%	-2.27 [-2.66, -1.88] -	-				
GF. CHEN 2015	4	1.5	64	6.1	2.1	90	10.0%	-2.10 [-2.67, -1.53]					
Huang 2016	2.36	0.51	70	3.29	0.46	70	13.5%	-0.93 [-1.09, -0.77]		-			
Kramer 2015	2.03	1.42	50	1.74	1.28	156	11.3%	0.29 [-0.15, 0.73]			+-	_	
Luo 2008	2.36	0.51	70	3.29	0.46	70	13.5%	-0.93 [-1.09, -0.77]		-			
Song 2010	1.48	0.38	64	1.93	0.82	109	13.4%	-0.45 [-0.63, -0.27]		-	с.		
Zhong 2010	2.36	0.51	25	3.29	0.46	42	13.0%	-0.93 [-1.17, -0.69]		-			
Zhu 2008	1.43	0.49	101	2.46	0.9	111	13.4%	-1.03 [-1.22, -0.84]					
Total (95% CI)			467			675	100.0%	-1.02 [-1.35, -0.68]		•			
Heterogeneity: Tau ² =	0.21; Cł	1 ² = 1	18.71, c	lf = 7 (F	v < 0.0	0001);	² = 94%	-	-2	-1	0	1	2
Test for overall effect:	Z = 5.89	(P < (0.00001)					Favou	rs HOLRE	T Fav	ours TUR	BT

Fig. 3 The results of catheterization time in meta-analysis

	н	DLRB	г	т	URBT			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
D'souza 2016	3.21	0.34	23	5.82	0.65	27	14.8%	-2.61 [-2.89, -2.33] —	-
GF. CHEN 2015	7.5	2.6	64	8.3	2.8	90	11.1%	-0.80 [-1.66, 0.06]	
Huang 2016	3.26	0.44	70	4.43	0.55	70	15.2%	-1.17 [-1.33, -1.01]	-
Kramer 2015	3.01	1.43	50	2.73	1.27	156	14.0%	0.28 [-0.16, 0.72]	+
Song 2010	2.88	0.63	64	3.55	1.2	109	14.9%	-0.67 [-0.94, -0.40]	
Zhong 2010	3.26	0.44	25	4.43	0.55	42	15.0%	-1.17 [-1.41, -0.93]	
Zhu 2008	2.93	0.68	101	4.43	1.06	111	15.0%	-1.50 [-1.74, -1.26]	-
Total (95% Cl)			397			605	100.0%	-1.11 [-1.65, -0.58]	◆
Heterogeneity: Tau ² =	0.49; Cł	ni² = 15	59.07, d	lf = 6 (P	< 0.0	0001);	² = 96%		
Test for overall effect:	Z = 4.07	(P < (0.0001)						-2 -1 U 1 2 Favours HOLRBT Favours TURBT

Fig. 4 The results of hospitalization time in meta-analysis

the large impact on recurrence by different chemotherapy schemes, a subgroup analysis was carried out, which showed that there was an insignificance in mitomycin C, epirubicin, pirarubicin, and subgroups that did not mention chemotherapy scheme (Fig. 5).

2-year recurrence

When the rate of 2-year recurrence was compared between two groups, pooled data from 8 studies including a total of 939 patients [9, 10, 12-17] revealed that the recurrence was

	HOLR	BT	TURB	вт		Odds Ratio	Odd	ls Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I <u>М-Н, Fi</u>	<u>xed, 95% Cl</u>			
1.8.1 mitomycin C											
D'souza 2016	2	23	3	27	6.1%	0.76 [0.12, 5.01]					
Zhu 2008	19	101	27	111	50.6%	0.72 [0.37, 1.40]	_	+			
Subtotal (95% CI)		124		138	56.7%	0.73 [0.39, 1.35]					
Total events	21		30								
Heterogeneity: Chi ² = ().00, df = ′	1 (P = (0.96); l² =	0%							
Test for overall effect: 2	Z = 1.01 (F	> = 0.3	1)								
1.8.2 epirubicin											
Zhong 2010	3	25	7	42	11.1%	0.68 [0.16, 2.92]		<u> </u>			
Subtotal (95% CI)		25		42	11.1%	0.68 [0.16, 2.92]					
Total events	3		7								
Heterogeneity: Not app	licable										
Test for overall effect: 2	Z = 0.52 (F	> = 0.6	1)								
1.8.3 pirarubicin											
Luo 2008	2	26	6	38	10.9%	0.44 [0.08, 2.40]					
Subtotal (95% CI)		26		38	10.9%	0.44 [0.08, 2.40]					
Total events	2		6								
Heterogeneity: Not applicable											
l est for overall effect: A	Z = 0.94 (H	J = 0.3	5)								
1.8.4 not mentioned											
Muraro 2005	10	50	11	50	21.3%	0.89 [0.34, 2.32]					
Subtotal (95% CI)		50		50	21.3%	0.89 [0.34, 2.32]					
Total events	10		11								
Heterogeneity: Not app	olicable										
Test for overall effect: 2	Z = 0.25 (F	⊃ = 0.8	1)								
Total (95% CI)		225		268	100.0%	0.72 [0.45, 1.16]					
Total events	36		54								
Heterogeneity: Chi ² = ().50, df = 4	4 (P = (0.97); l² =	0%					400		
Test for overall effect: 2	Z = 1.34 (F	⊃ = 0.1	8)						100		
Test for subgroup diffe	rences: Cl	hi² = 0.	50, df = 3	(P = 0	.92), I ² = 0	1%					

Fig. 5 The results of 1-year recurrence in meta-analysis

	HOLR	вт	TURE	вт		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
1.6.1 mitomycin C							
D'souza 2016	4	23	7	27	4.8%	0.60 [0.15, 2.39]	
Song 2010	20	63	44	107	20.0%	0.67 [0.35, 1.28]	
Zhu 2008	33	101	44	111	25.4%	0.74 [0.42, 1.30]	
Subtotal (95% CI)		187		245	50.2%	0.70 [0.46, 1.05]	
Total events	57		95				
Heterogeneity: Chi ² = 0).10, df = :	2 (P = 0).95); l² =	0%			
Test for overall effect: 2	Z = 1.74 (I	P = 0.03	8)				
1.6.2 epirubicin							
Huang 2016	8	62	q	60	7 2%	0.84 [0.30, 2.34]	
Zhong 2010	6	25	13	42	6.6%	0.70 [0.23, 2.17]	
Subtotal (95% CI)	0	87	10	102	13.8%	0.77 [0.36, 1.65]	
Total events	14		22				
Heterogeneity: $Chi^2 = 0$).05. df = 1	1 (P = ().82): l ² =	0%			
Test for overall effect: 2	Z = 0.66 (I	P = 0.5	1)				
	```		,				
1.6.3 theprubicine							
GF. CHEN 2015	21	64	37	90	18.6%	0.70 [0.36, 1.37]	
Luo 2008	3	26	9	38	5.8%	0.42 [0.10, 1.73]	
Subtotal (95% CI)		90		128	24.4%	0.63 [0.35, 1.16]	
Total events	24		46				
Heterogeneity: Chi ² = 0	).41, df =	1 (P = 0	).52); l² =	0%			
Test for overall effect: 2	Z = 1.49 (I	P = 0.14	4)				
1.6.4 not mentioned							
Muraro 2005	14	50	18	50	11 7%	0.69 [0.30, 1.61]	
Subtotal (95% CI)		50		50	11.7%	0.69 [0.30, 1.61]	
Total events	14		18				
Heterogeneity: Not app	licable						
Test for overall effect: 2	Z = 0.86 (I	P = 0.3	9)				
		444		505	400.00/	0.00.00.00.000	
Total (95% CI)	100	414	404	525	100.0%	0.69 [0.52, 0.92]	$\bullet$
I otal events	109		181	00/			
Heterogeneity: $Chi^2 = C$	1.72,  at = 7 - 9.50  f	/ (P = 1	1.00); I ² =	0%			0.1 0.2 0.5 1 2 5 10
Test for overall effect: 2	∠ = 2.50 (I	r = 0.0	1) 17 - 16 - 0	(D – 2	00) 12 - 0	0/	Favours HOLRBT Favours TURBT
l est for subgroup differ	rences: C	nı∸ = 0.1	17, at = 3	(P = 0)	.98), I <u>+</u> = 0	70	

Fig. 6 The results of 2-year recurrence in meta-analysis

significantly higher in TURBT group (OR = 0.69; 95% CI [0.51, 0.94], P = 0.02). However, in the subgroup analysis, all results became insignificant in mitomycin C, epirubicin, pirarubicin subgroups, and in the subgroup that did not describe chemotherapy scheme (Fig. 6).

#### Complications

Four studies [10, 12, 15, 17] evaluated the incidence of obturator nerve reflex, which revealed significantly lower rate of occurrence in the HOLRBT group (OR = 0.06; 95% CI [0.01, 0.23], P < 0.0001) (Fig. 7).



Fig. 7 The results of obturator nerve reflex in meta-analysis

	HOLR	вт	TURE	вт		Odds Ratio	Odds Ra	tio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 9	)5% Cl
D'souza 2016	0	23	3	27	12.3%	0.15 [0.01, 3.04]		
GF. CHEN 2015	0	64	6	90	20.9%	0.10 [0.01, 1.82]		
Huang 2016	0	70	5	70	21.3%	0.08 [0.00, 1.56]		
Luo 2008	0	26	5	38	17.2%	0.11 [0.01, 2.17]		
Song 2010	0	64	4	109	12.9%	0.18 [0.01, 3.43]		-
Zhong 2010	0	25	1	42	4.3%	0.54 [0.02, 13.83]		
Zhu 2008	1	101	3	111	11.0%	0.36 [0.04, 3.52]		-
Total (95% CI)		373		487	100.0%	0.16 [0.06, 0.47]	•	
Total events	1		27					
Heterogeneity: Chi ² = 1	.35, df = 6	6 (P = 0	).97); l² =	0%				
Test for overall effect: 2	z = 3.37 (f	= 0.0	008)				Favours HOLRBT Fa	vours TURBT

Fig. 8 The results of bladder perforation in meta-analysis

Additionally, seven studies including 860 patients [9, 10, 12, 14–17] were pooled, which presented that the incidence of bladder perforation was significant lower in the HOLRBT group (OR = 0.15; 95% CI [0.05, 0.45], P = 0.0008) (Fig. 8).

What is more, six studies including 648 patients [9, 10, 12, 14–16] evaluated the incidence of bladder irritation and revealed a significant difference between two groups and lower incidence of bladder irritation in HOLRBT group (OR = 0.45; 95% CI [0.31, 0.66], P < 0.0001) (Fig. 9).

When urethral stricture was compared between HOLRBT and TURBT groups, 4 studies [10, 12, 15, 16] including 444 patients were pooled. The result of meta-analysis showed that there was an insignificance in urethral stricture between two groups (OR = 0.86, 95% CI [0.37, 1.98], P = 0.73) (Fig. 10).

#### Sensitivity analysis and publication bias

To analyze the potential publication bias, a funnel plot of operation time was performed, which revealed that 2 studies had potential publication bias. After the studies were excluded, similar results in all outcomes of interest were shown (Fig. 11).

## Discussion

With the increasing of patients with NMIBC, it became a key issue how to improve the survival and quality of patients' life. Nowadays, TURBT still played an important role in the diagnosis and treatment of NMIBC, because it could provide adequate tissue for pathological examination followed with all visible tumors being effectively removed [18, 19]. However, thermal injury was the main factor which leads to complications by TURBT, due to the radiofrequency that had developed an electrical resistance at a temperature that ranged from 100 to 300 °C in the treatment site [20]. According to the reason above, the occurrence of obturator nerve reflex was frequent during TURBT, especially for tumors at the lateral wall of bladder, which possibly leaded to bladder perforation [21]. In order to avoid these complications, inadequate resection depth of the tumors might occur [22]. Meanwhile, the time to catheterization and hospitalization might be longer by thermal injury.

Fortunately, after laser was firstly applied in urology in 1978 [23], holmium laser was gradually used in the resection of bladder tumors since 2001 [24]. In the beginning, the most obvious shortage of laser was unable to reach sufficient tissue



Fig. 9 The results of bladder irritation in meta-analysis

	HOLR	вт	TURE	BT		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Huang 2016	3	70	4	70	31.7%	0.74 [0.16, 3.43]	
Luo 2008	0	26	3	38	23.3%	0.19 [0.01, 3.87]	
Song 2010	3	64	4	109	23.3%	1.29 [0.28, 5.96]	<b>■</b>
Zhong 2010	3	25	4	42	21.7%	1.30 [0.27, 6.33]	
Total (95% CI)		185		259	100.0%	0.86 [0.37, 1.98]	-
Total events	9		15				
Heterogeneity: Chi ² = 1	.52, df = 3	3 (P = 0	).68); I ² =	0%			
Test for overall effect: 2	Z = 0.35 (I	P = 0.73	3)				Favours HOLRBT Favours TURBT

Fig. 10 The results of urethral stricture in meta-analysis

for pathological examination in the treatment of NMIBC. Nonetheless, holmium laser can not only offer adequate tissue for pathological examination, and even accomplish en bloc resection of NMIBC [25, 26]. Holmium laser had a wavelength of 2100 nm. At this wavelength, the tissue penetration depth of the laser was about 400  $\mu$ m, which was considered safely. The temperature of the treatment regions in HOLRBT ranged from 40 to 75 °C, which was large lower than in TURBT. Thus, the thermal injury in the treatment site was minimal as well [26]. It made a necessary to compare these two technologies.

Our results showed that the time of catheterization and hospitalization was significantly shorter in the HOLRBT group than the TURBT group; however, there was no significant difference in operation time. The same conclusions were reported by Teng et al. [27]. For the time of catheterization and hospitalization, rapider postoperative recovery was shown in the HOLRBT group because of thermal damage caused by TURBT. Nonetheless, significant heterogeneities among studies could be found, and the accuracy of results might be influenced. Our study revealed that HOLRT had a significant benefit in 2-year recurrence compare with TUBRT, which could be calculated to be 26.1% in HOLRBT group and 34.3% in TURBT group, respectively. In addition, the rate of 1-year recurrence was insignificant. Considering the difference of postoperative intravesical instilled chemotherapy scheme, subgroup analysis was carried out. Though postoperative adjuvant intravesical chemotherapy was an important factor which may affected the recurrence of cancer [28], no significant difference was found in our study. However, more evidence should be discovered to verify this conclusion.

Our study further confirmed the incidences of several perioperative complications, including obturator nerve reflex, bladder perforation, and bladder irritation, which presented large advantages in the HOLRBT group. The rate of obturator nerve reflex, bladder perforation, and bladder irritation could be calculated to be 0%, 0.2%, and 22.0% in HOLRBT group and 11.2%, 5.3%, and 39.1% in TURBT group, respectively. In addition, our study showed that there was an insignificance in the rate of urethral stricture between two groups, which could be calculated to be 4.8% in HOLRBT group and 5.8%



Fig. 11 Funnel plot

in TURBT group, respectively. Based on these results, it seemed that HOLRBT would be safer than TURBT for patients with NMIBC.

Above all, some limitations should be taken into consideration in this study. Firstly, only one RCT was included for analysis, which would lower the quality of pooled results. Secondly, some important parameters were not analyzed because the description of them could not be uniformed, such as pre- and postoperative bleeding. Thirdly, high heterogeneity could be observed in outcomes of operation time, catheterization time, and hospitalization time. These might due to the differences of patient's condition, surgeons' technique and custom, etc.

# Conclusions

Based on the results of our meta-analysis, HOLRBT showed similar effectiveness and superior safety than TURBT for patients with NMIBC, though sporadical insignificance between two groups was found. However, more high-quality clinical trials were needed to further confirm our conclusions.

**Data availability** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### **Compliance with ethical standards**

**Ethics approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Statement of informed consent** Informed consent was obtained from all individual participants included in the study.

Abbreviations HOLRBT, Holmium laser resection of the bladder tumor; TURBT, Transurethral resection of the bladder tumor; NMIBC, Non-muscle-invasive bladder cancer; PRISMA, Preferred reporting items for systematic review and meta-analysis protocols; NOS, Newcastle-Ottawa scale; RCT, Randomized controlled studies; CS, Cohort studies; CCS, Case-control studies; OR, Odd ratio; MD, Mean difference; CI, Confidence intervals; LOE, Level of evidence; NA, Not available

## References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac. 21492
- Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234–241. https://doi.org/10.1016/j.eururo.2012.07.033

- Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461
- Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer, Lancet (London, England). 374(9685):239–249. https://doi.org/10. 1016/s0140-6736(09)60491-8
- Zarrabi A, Gross AJ (2011) The evolution of lasers in urology. Ther Adv Urol 3(2):81–89. https://doi.org/10.1177/1756287211400494
- Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (London, England) 8(5):336–341. https://doi.org/10.1016/j.ijsu.2010.02.007
- 7. Phillips B (2004) GRADE: levels of evidence and grades of recommendation. Arch Dis Child 89(5):489
- Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/ s10654-010-9491-z
- Chen GF, Shi TP, Wang BJ, Wang XY, Zang Q (2015) Efficacy of different resections on non-muscle-invasive bladder cancer and analysis of the optimal surgical method. J Biol Regul Homeost Agents 29(2):465–470
- Huang JH, Hu YY, Liu M, Wang GC, Peng B, Yao XD (2016) Comparative study of 2 um laser versus holmium laser for the resection of non-muscle invasive bladder cancer. Int J Clin Exp Med 9(12):23618–23623
- Kramer MW, Rassweiler JJ, Klein J et al (2015) En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol 33(12):1937–1943. https://doi.org/10.1007/s00345-015-1568-6
- Luo Y, Cao ZG, Liu J, Su JH, Zhu JG, Xu Z (2008) A comparison of clinical outcome between holmium laser resection and transurethral resection for superficial bladder carcinoma. Tumor 28(11): 1001–1003. https://doi.org/10.3781/j.issn.1000-7431.2008.11.022
- Muraro GB, Grifoni R, Spazzafumo L (2005) Endoscopic therapy of superficial bladder cancer in high-risk patients: holmium laser versus transurethral resection. Surg Technol Int 14:222–226
- Verma A, D'Souza N (2016) Holmium laser transurethral resection of bladder tumor: our experience. Indian J Urol 32
- Xishuang S, Deyong Y, Xiangyu C et al (2010) Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer. J Endourol 24(1):69–73. https://doi.org/10. 1089/end.2009.0171
- Zhong C, Guo S, Tang Y, Xia S (2010) Clinical observation on 2 micron laser for non-muscle-invasive bladder tumor treatment: single-center experience. World J Urol 28(2):157–161. https://doi. org/10.1007/s00345-010-0532-8
- Zhu Y, Jiang X, Zhang J, Chen W, Shi B, Xu Z (2008) Safety and efficacy of holmium laser resection for primary nonmuscle-invasive bladder cancer versus transurethral electroresection: single-center experience. Urology 72(3):608–612. https://doi.org/10.1016/j. urology.2008.05.028
- Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05. 041
- Herrmann TR, Liatsikos EN, Nagele U, Traxer O, Merseburger AS (2012) EAU guidelines on laser technologies. Eur Urol 61(4):783– 795. https://doi.org/10.1016/j.eururo.2012.01.010
- Issa MM (20008) Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. J Endourol 22: 1587–1595

- Khorrami MH, Javid A, Saryazdi H, Javid M (2010) Transvesical blockade of the obturator nerve to prevent adductor contraction in transurethral bladder surgery. J Endourol 24(10):1651–1654. https://doi.org/10.1089/end.2009.0659
- Mariappan P, Zachou A, Grigor KM (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57(5):843–849. https://doi.org/10.1016/j.eururo.2009.05.047
- Staehler G, Schmiedt E, Hofstetter A (1978) Destruction of bladder neoplasms by means of transurethral neodym-YAG-laser coagulation. Helv Chir Acta 45(3):307–311
- 24. Saito S (2001) Transurethral en bloc resection of bladder tumors. J Urol 166(6):2148–2150

- Hurle R, Lazzeri M, Colombo P et al (2016) "En bloc" resection of nonmuscle invasive bladder cancer: a prospective single-center study. World J Urol 33:1937–1943
- 26. Kramer MW, Wolters M, Herrmann TR (2016) En bloc resection of bladder tumors: ready for prime time? Eur Urol 69:967–968
- Teng JF, Wang K, Yin L, Qu FJ, Zhang DX, Cui XG, Xu DF (2013) Holmium laser versus conventional transurethral resection of the bladder tumor. Chin Med J 126(9):1761–1765
- Oosterlinck W, Decaestecker K (2018) Update on early instillation of chemotherapy after transurethral resection of non-muscleinvasive bladder cancer. Expert Rev Anticancer Ther 18(5):437– 443. https://doi.org/10.1080/14737140.2018.1451748

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.